The UK and US have secured a significant trade agreement that will maintain zero levies on British medicine shipments being sold in the American market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to increase expenditure on medicines through the public health system. This pledge ensures that duties on these crucial goods will stay at zero for a period of 36 months.
This deal follows previous warnings to dramatically increase tariffs on branded pharmaceutical products, with potential rates floated reaching one hundred percent.
"This agreement between the UK reinforces the international landscape for innovative medicines and brings long-overdue equity to U.S.–U.K. medicine commerce," a statement said.
Commercial Significance
Medicines represent one of the UK's largest exports to the America, which is easily the largest buyer for large companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period to the end of last September, the UK sold pharmaceutical products totaling billions to the US. This amount made up nearly one-fifth of British export trade in that period.
"This agreement protects employment, boosts capital expenditure and facilitates the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary remarked.
Specific British Pledges
The deal involves several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it judges new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to raise total health service expenditure on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum manufacturers must return to the NHS to prevent overspending will be restricted at fifteen percent. Last year, refunds exceeded 20%.
Industry Background
This agreement takes place against a protracted row between the sector and the UK government over medicine costs and NHS adoption.
The disagreement were heightened by claims that American customers were charged a premium for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been delayed or scrapped, while major expansions have been pledged toward projects in the United States.
One official publicly accepted that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had shrunk as a proportion of its total funding over the previous ten-year period.
